Monday, August 23, 2021 1:27:36 PM
A number of sources lauded the Oramed/Premas development as a breakthrough of blockbuster proportions, which has resulted in the Board of Directors of MyMD to consider spinning off their shares of Oravax to existing shareholders. Were this to be the case, if said spinoff were based on the current circumstances, MyMD (Florida) shareholders would receive 80% of those shares, and MyMD (Akers) 20%, while it was Akers that brought the Premas vaccine to the merger table.
This unfairness might require an adjustment in the normal spinoff procedure, for example allowing MyMD (Akers) shareholders to receive 1 share of Oravax for each 100 shares of MyMD owned, but only allowing MyMD (Florida) shareholders to receive 1 share of Oravax for each 400 shares of MyMD owned.
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM